摘要
目的:研究人疱疹病毒6型(human herpesvirus-6,HHV-6)感染与神经胶质瘤的关系。方法:巢式PCR法检测40例神经胶质瘤样本和13例正常脑组织样本中HHV-6、人巨细胞病毒(human cytomegalovirus,HCMV)、HHV-7 DNA序列。免疫组化染色法检测神经胶质瘤样本和正常脑组织样本中HHV-6、HCMV、HHV-7抗原的表达。结果:巢式PCR法检测结果显示,神经胶质瘤组织HHV-6 DNA阳性率为42.5%,正常脑组织HHV-6 DNA阳性率为7.7%(P=0.020),神经胶质瘤组织HCMV、HHV-7DNA阳性率分别为20.0%和5.0%,正常脑组织未检测到HCMV和HHV-7 DNA(P值分别为0.087和0.566)。进一步用免疫组化染色法检测HHV-6早期抗原p41的表达,神经胶质瘤组织阳性率为27.5%,正常脑组织未见阳性表达(P=0.030)。同时检测HHV-6晚期抗原gp116/64/54的表达,神经胶质瘤组织阳性率为32.5%,正常脑组织未见阳性表达(P=0.014)。用HCMV pp65抗体进行免疫组化染色后发现其在神经胶质瘤中阳性率为12.5%,正常脑组织未见阳性表达(P=0.229)。HHV-7 pp85抗原在神经胶质瘤样本和正常脑组织样本中均未检出阳性表达。结论:根据PCR和免疫组化的检测结果,HHV-6感染在神经胶质瘤和正常脑组织中具有显著性差异,HHV-6感染在神经胶质瘤的病因和发展过程中起了一定作用。
Objective: To study the relationship between human herpesvirus(HHV)-6 infection and glioma.Methods:HHV-6,human cytomegalovirus(HCMV) and HHV-7 DNA in glioma samples(n = 40) and control samples(n = 13) were detected by nested PCR.The expression of HHV-6,HCMV and HHV-7 was detected by immunohistochemistry(IHC).Results:HHV-6 DNA was positive in 17/40(42.5%) of glioma samples and 1/13(7.7%) of normal brain samples(P = 0.020),while the positive rates of HCMV and HHV-7 DNA were 20.0% and 5.0% in glioma,respectively.HCMV and HHV-7 DNA hadn’t been found in normal brain samples(P = 0.087 and 0.566 respectively).HHV-6 late antigen p41 was expressed in 11/40(27.5%) of tumors and 0 of the controls(P = 0.030),while HHV-6 early antigen gp116/64/54 was expressed in 13/40(32.5%) of tumors and 0 of the controls(P = 0.014).HCMV pp65 antigen was expressed in 5/40(12.5%) of glioma samples and 0/13 of the normal brain controls(P = 0.229).HHV-7 pp85 antigen hadn’t been found in tumors and normal brain samples.Conclusion:Based on the results of nested PCR and immunohistochemistry,significant difference of HHV-6 infection between glioma and normal brain tissue was confirmed.HHV-6 infection may play a role on the pathagenesis and progression of glioma.
出处
《南京医科大学学报(自然科学版)》
CAS
CSCD
北大核心
2012年第8期1052-1056,共5页
Journal of Nanjing Medical University(Natural Sciences)
基金
国家自然科学基金资助(30972784)
江苏省医学重点人才工程(135工程)资助(RC2002075)